

Remarks/Arguments

Claims 5-7, 9-14, 16-21, 23-28, 30-35, and 37-61 are pending. Of those, claims 5-7, 9-14, 16-21, 23-28, 30-35, 37-39, and 55-61 are withdrawn.

Applicant was required to elect one of the following groups of invention:


- I. Claims 40-54, drawn to a composition comprising a placental stem cell isolated from the amnion wherein the composition is enriched for cells that express at least one marker selected from the recited Markush group, classified in class 424, subclass 93.1.
- II. Claims 55-61, drawn to a method of making the composition comprising a placental stem cell isolated from the amnion wherein the composition is enriched for cells that express at least one marker selected from the recited Markush group, classified in class 435, subclass 325.

In response, Applicants elect to pursue the claims of Group I in this application.

Election of Group I further required election of a species from the markers of the recited Markush group. Accordingly, Applicants have elected the species SSEA-4. Claims 40-43 and 46-54 read on the elected species. Applicants respectfully request that, upon allowance of a generic claim, claims directed to non-elected species including all the limitations of the generic claim be considered in accordance with 37 C.F.R. § 1.141 and ultimately allowed.

In view of the foregoing amendment, the application is now believed to be in condition for examination. Prompt consideration and allowance of the pending claims is respectfully requested.

Respectfully submitted,
KENYON & KENYON LLP

By: 
Lawrence P. Casson
Reg. No. 46,606

Date: May 8, 2006

One Broadway
New York, NY 10004
Telephone: (212) 425-7200
Facsimile: (212) 425-5288